Methods for selective immunomodulation
OwnerSalah-Dine Chibout, Andre Cordier +2inventors
InventorsSalah-Dine Chibout, Andre Cordier, Jeanne Kehren, Henrietta Denise Moore
Life of this patent
Estimating the term…
Abstract
This invention relates to methods to produce selective immunomodulation in epithelial tissues to treat epithelial inflammatory disorders. This invention provides methods for the use of pimecrolimus to treat epithelial inflammatory disorders, including asthma and inflammatory bowel disease while minimizing systemic side effects.
Claims52
A method of treating or preventing an epithelial inflammatory disorder (EID) in a human while minimizing the degree of systemic immunosuppression, comprising administering to a human in need of such treatment or prevention of an EID an amount of pimecrolimus sufficient to ameliorate at least one symptom of the EID but which produces less systemic immunosuppression than a clinically equally effective dose of an orally active corticosteroid.
A method of treating or preventing an epithelial inflammatory disorder in a human while minimizing the degree of systemic immunosuppression, comprising administering to a human in need of such treatment or prevention of an EID an amount of pimecrolimus sufficient to ameliorate at least one symptom of the EID but which produces a blood level of pimecrolimus which is less than that required to produce systemic immunosuppression.
A method of treating or preventing an EID in a human while minimizing the degree of systemic immunosuppression comprising administering to a human in need of such treatment or prevention of an EID an amount of pimecrolimus sufficient to ameliorate at least one symptom of the EID but which produces a blood level of pimecrolimus which is less than that required to produce any of the adverse side effects of;
- opportunistic infections produced by bacterial, viral or fungal pathogens or lymphoproliferative disorders, or lymphomas or other malignancies in said human.
A method of treating or preventing an EID in a human while minimizing the degree of systemic immunosuppression comprising administering to a human in need of such treatment or prevention of an EID an amount of pimecrolimus sufficient to ameliorate at least one symptom of the EID but which produces a blood level of pimecrolimus which is less than that required to produce a mean steady-state area under the curve (AUC) over 24 hours of 1000 ng·h/mL.
A method of treating or preventing an EID in a human while minimizing the degree of systemic immunosuppression comprising administering to a human in need of such treatment or prevention of an EID an amount of pimecrolimus sufficient to ameliorate at least one symptom of the EID but which produces a blood level of pimecrolimus with a trough level in a steady-state condition of greater than 7 ng/mL but less than 18 ng/mL.
A method of treating or preventing an EID in a human while minimizing the degree of systemic immunosuppression comprising administering to a human in need of such treatment or prevention of an EID an amount of pimecrolimus sufficient to ameliorate at least one symptom of the EID but which produces a blood level, in a steady-state condition, where Cmax is less than 70 ng/mL.
A method of treating or preventing an epithelial inflammatory disorder (EID) in a human, comprising administering to a human in need of such treatment or prevention of an epithelial inflammatory disorder, an amount of pimecrolimus sufficient to ameliorate at least one symptom of the epithelial inflammatory disorder.
Dependencies are inferred from the claim text.